Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Date | Form | Description | XBRL | Pages | |
---|---|---|---|---|---|
06/20/25 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
![]() |
11 | |
06/12/25 | 8-K | Current report |
![]() |
![]() ![]() ![]() |
77 |
06/12/25 | 424B5 | Prospectus [Rule 424(b)(5)] |
![]() |
86 | |
06/11/25 | 424B5 | Prospectus [Rule 424(b)(5)] |
![]() |
86 | |
06/11/25 | 8-K | Current report |
![]() |
![]() ![]() ![]() |
48 |
06/10/25 | 8-K | Current report |
![]() |
![]() ![]() ![]() |
5 |
06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 | |
06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 | |
06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 | |
06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 |